GBIO News and Press, Generation Bio Co. From 10/22/21

Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potential to address inherited retinal diseases with full gene replacement Unifor...

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will partici...

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) ...

Gainers: Corvus Pharmaceuticals (NASDAQ:CRVS) +73%, Innate Pharma IPHA +51%, SmileDirectClub (NASDAQ:SDC) +12%, Biomerica (NASDAQ:BMRA) +9%, I-Mab (NASDAQ:IMAB) +6%. Losers: Protagonist Therapeutics PTGX -62%, TCR2 Therapeutics TCRR -31%,...

Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSimple (NASDAQ:TSP) +20%. CynergisTek (...

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. “T...

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate...

Generation Bio (GBIO) plans to deploy next-generation rapid enzymatic synthesis ((RES)) for manufacturing of its closed-ended DNA (ceDNA) constructs across all portfolio programs. The company has signed a lease agreement to build out a state-of-the-art cGMP facility of approx. 104,000 square ...

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control o...

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William B...